Alaunos Therapeutics (TCRT) Equity Average (2010 - 2026)

Alaunos Therapeutics has reported Equity Average for 17 years, with the latest figure at $1.7 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 11.76% year-over-year to $1.7 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (up 11.76% YoY), and the FY2025 full-year result was $2.1 million, down 49.07% from the prior year.
• Equity Average for Q1 2026 stood at $1.7 million, down from $2.5 million in the prior quarter.
• The five-year high for Equity Average was $53.6 million in Q1 2022, with the low at $1.6 million in Q1 2025.
• Historically, Equity Average has averaged $16.7 million across 5 years, with a median of $5.6 million in 2024.
• Annual changes were most pronounced in 2024 — Equity Average plunged 83.68% — and 2026, when it increased 11.76%.
• Alaunos Therapeutics' Equity Average stood at $35.3 million in 2022, then slumped by 71.41% to $10.1 million in 2023, then tumbled by 76.31% to $2.4 million in 2024, then advanced by 4.51% to $2.5 million in 2025, then slumped by 30.28% to $1.7 million in 2026.
• The last three Equity Average figures came in at $1.7 million (Q1 2026), $2.5 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.